Molecular imaging for monitoring treatment response in breast cancer patients

Frederike Bensch, Michel van Kruchten, LaetitiaE. Lamberts, Carolien P. Schroder, Geke A. P. Hospers, Adrienne H. Brouwers, Marcel A. T. M. van Vugt, Elisabeth G. E. de Vries*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

14 Citations (Scopus)

Abstract

Currently, tumour response following drug treatment is based on measurement of anatomical size changes. This is often done according to Response Evaluation Criteria in Solid Tumours (RECIST) and is generally performed every 2-3 cycles. Bone metastases, being the most common site of distant metastases in breast cancer, are not measurable by RECIST. The standard response measurement provides no insight in changes of molecular characteristics. In the era of targeted medicine, knowledge of specific molecular tumour characteristics becomes more important. A potential way to assess this is by means of molecular imaging. Molecular imaging can visualise general tumour processes, such as glucose metabolism with F-18-fluorodeoxyglucose (F-18-FDG) and DNA synthesis with F-18-fluorodeoxythymidine (F-18-FLT). In addition, an increasing number of more specific targets, such as hormone receptors, growth factor receptors, and growth factors can be visualised. In the future molecular imaging may thus be of value for personalised treatment-selection by providing insight in the expression of these drug targets. Additionally, when molecular changes can be detected early during therapy, this may serve as early predictor of response. However, in order to define clinical utility of this approach results from (ongoing) clinical trials is required. In this review we summarise the potential role of molecular imaging of general tumour processes as well as hormone receptors, growth factor receptors, and tumour microenvironment for predicting and monitoring treatment response in breast cancer patients. (C) 2013 Elsevier B.V. All rights reserved.

Original languageEnglish
Pages (from-to)2-11
Number of pages10
JournalEuropean Journal of Pharmacology
Volume717
Issue number1-3
DOIs
Publication statusPublished - 5-Oct-2013

Keywords

  • Molecular imaging
  • Breast cancer
  • PET
  • Response monitoring
  • RECIST
  • POSITRON-EMISSION-TOMOGRAPHY
  • ENDOTHELIAL GROWTH-FACTOR
  • ANDROGEN RECEPTOR EXPRESSION
  • HSP90 INHIBITOR NVP-AUY922
  • PET TRACER UPTAKE
  • TUMOR RESPONSE
  • NEOADJUVANT CHEMOTHERAPY
  • ESTROGEN-RECEPTORS
  • F-18-FDG PET
  • HORMONE-RECEPTORS

Cite this